|
FR2724320B1
(fr)
|
1994-09-13 |
1996-12-20 |
Transgene Sa |
Nouvel implant pour le traitement des maladies acquises
|
|
WO1997044461A2
(en)
|
1996-05-22 |
1997-11-27 |
Novopharm Biotech, Inc. |
Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
CN100447244C
(zh)
|
1999-08-17 |
2008-12-31 |
比奥根艾迪克Ma公司 |
Baff受体(bcma),一种免疫调节剂
|
|
WO2001087977A2
(en)
|
2000-05-12 |
2001-11-22 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
WO2002066516A2
(en)
|
2001-02-20 |
2002-08-29 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
JP2003111595A
(ja)
|
2001-06-25 |
2003-04-15 |
Kyogo Ito |
腫瘍抗原
|
|
US20080267965A1
(en)
|
2002-02-21 |
2008-10-30 |
Kalled Susan L |
Use of Bcma as an Immunoregulatory Agent
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
DK1629011T3
(da)
|
2003-05-31 |
2010-05-03 |
Micromet Ag |
Humane anti-humane-DC3-bindingsmolekyler
|
|
MXPA06004035A
(es)
|
2003-10-16 |
2006-08-31 |
Micromet Ag |
Aglutinantes cd3 de-inmunizados multi-especificos.
|
|
JP2007509064A
(ja)
|
2003-10-20 |
2007-04-12 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Ｂａｆｆアンタゴニストのための治療養生法
|
|
US7947805B2
(en)
|
2004-12-23 |
2011-05-24 |
Merck Serono S.A. |
BCMA polypeptides and uses thereof
|
|
HUE025945T2
(en)
|
2005-02-15 |
2016-07-28 |
Univ Duke |
Anti-CD19 antibodies and their applications in oncology
|
|
RU2008129827A
(ru)
|
2005-12-21 |
2010-01-27 |
МЕДИММЬЮН, ЭлЭлСи (US) |
МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
|
|
SG177907A1
(en)
|
2006-06-14 |
2012-02-28 |
Macrogenics Inc |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
AU2008208288B2
(en)
|
2007-01-24 |
2014-04-03 |
Kyowa Kirin Co., Ltd. |
Genetically recombinant antibody composition having enhanced effector activity
|
|
CN101678106B
(zh)
|
2007-03-27 |
2013-06-05 |
津莫吉尼蒂克斯公司 |
用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合
|
|
EP2144928A2
(en)
|
2007-04-20 |
2010-01-20 |
Amgen Inc. |
Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor
|
|
EP2370467B1
(en)
|
2008-10-01 |
2016-09-07 |
Amgen Research (Munich) GmbH |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
|
MX341884B
(es)
|
2009-03-10 |
2016-09-07 |
Biogen Ma Inc |
Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
|
|
CA3255551A1
(en)
|
2010-03-26 |
2025-04-15 |
Memorial Sloan-Kettering Cancer Center |
MUC16 ANTIBODIES AND METHODS OF USE
|
|
AU2011295968B2
(en)
|
2010-09-01 |
2017-01-05 |
Biogen Ma Inc. |
Rapid generation of anti-idiotypic antibodies
|
|
EP3974453A3
(en)
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
RU2018108836A
(ru)
|
2011-02-04 |
2019-03-14 |
Дженентек, Инк. |
ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
|
US20120213768A1
(en)
|
2011-02-19 |
2012-08-23 |
Baylor Research Institute |
Diagnostic and Therapeutic Uses for B Cell Maturation Antigen
|
|
TWI743461B
(zh)
|
2011-03-28 |
2021-10-21 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
KR101972446B1
(ko)
|
2011-05-27 |
2019-04-25 |
글락소 그룹 리미티드 |
Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
HUE033245T2
(hu)
|
2011-12-19 |
2017-11-28 |
Synimmune Gmbh |
Bispecifikus ellenanyag molekula
|
|
CA2861491C
(en)
|
2012-02-13 |
2020-08-25 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
CA2866699A1
(en)
|
2012-03-09 |
2013-09-12 |
Ucl Business Plc |
Chemical modification of antibodies
|
|
JP2015524255A
(ja)
|
2012-07-13 |
2015-08-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
|
|
WO2014122143A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
Method for the selection of antibodies against bcma
|
|
WO2015006749A2
(en)
|
2013-07-12 |
2015-01-15 |
Zymeworks Inc. |
Bispecific cd3 and cd19 antigen binding contructs
|
|
EP3060059A4
(en)
|
2013-10-25 |
2017-11-01 |
Board of Regents, The University of Texas System |
Polyclonal gamma delta t cells for immunotherapy
|
|
BR112016018100A2
(pt)
|
2014-02-07 |
2018-02-20 |
Univ Mcmaster |
acoplador antigênico de células t trifuncional, métodos e usos do mesmo
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
WO2016180468A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Biontech Cell & Gene Therapies Gmbh |
Claudin-18.2-specific immunoreceptors and t cell epitopes
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
US20210206826A1
(en)
|
2015-11-19 |
2021-07-08 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
|
CA3032838A1
(en)
|
2016-08-04 |
2018-02-08 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
CN108250302A
(zh)
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
CN111479925B
(zh)
|
2017-10-12 |
2024-03-08 |
麦克马斯特大学 |
具有y182t突变的t细胞-抗原偶联物及其方法和用途
|
|
US20220127570A1
(en)
*
|
2018-05-03 |
2022-04-28 |
Cafa Therapeutics Limited |
Immune effector cell and use thereof
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
JP7404279B2
(ja)
|
2018-07-17 |
2023-12-25 |
トリウムビラ イミュノロジクス ユーエスエー，インク． |
様々な構築物最適化を備えたｔ細胞抗原カプラ
|
|
CN113490689B
(zh)
|
2019-02-01 |
2024-06-04 |
恺兴生命科技(上海)有限公司 |
Tcr融合蛋白及表达tcr融合蛋白的细胞
|
|
CN114206935B
(zh)
*
|
2019-05-24 |
2024-01-12 |
三优生物医药(上海)有限公司 |
新型cldn18.2结合分子
|
|
AU2022283819A1
(en)
|
2021-06-01 |
2024-01-04 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
*
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|